Article Type
Article
Changed
Fri, 02/01/2019 - 09:02
Display Headline
COX-2 inhibitors and cardiovascular risk: Point and counterpoint
Author(s)
Brian F. Mandell, MD, PhD
Article PDF
content_68_957.pdf
Author and Disclosure Information

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; ccjm@ccf.org

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.

Issue
Cleveland Clinic Journal of Medicine - 68(11)
Publications
Cleveland Clinic Journal of Medicine
Topics
Vascular
Rheumatology
Cardiology
Drug Therapy
Page Number
957-960
Sections
Editorial
Author(s)
Brian F. Mandell, MD, PhD
Author(s)
Brian F. Mandell, MD, PhD
Author and Disclosure Information

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; ccjm@ccf.org

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.

Author and Disclosure Information

Brian F. Mandell, MD, PhD
Department of Rheumatic and Immunologic Diseases and Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, FACR, Cleveland Clinic Journal of Medicine, NA32,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; ccjm@ccf.org

Dr. Mandell has received honoraria, research support, or donations to educational programs from the Centocor, Merck, Pfizer, Searle, SmithKline Beecham, and Wyeth Pharmaceutical corporations.

Article PDF
content_68_957.pdf
Article PDF
content_68_957.pdf
Related Articles
COX-2 inhibitors: Balancing the hope, the hype, and the concern
COX-2 inhibitors and cardiovascular risk: The data are inconclusive, and these drugs are needed
COX-2 inhibitors and cardiovascular risk: We defend our data and suggest caution
Issue
Cleveland Clinic Journal of Medicine - 68(11)
Issue
Cleveland Clinic Journal of Medicine - 68(11)
Page Number
957-960
Page Number
957-960
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Topics
Vascular
Rheumatology
Cardiology
Drug Therapy
Article Type
Article
Display Headline
COX-2 inhibitors and cardiovascular risk: Point and counterpoint
Display Headline
COX-2 inhibitors and cardiovascular risk: Point and counterpoint
Sections
Editorial
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media